Begin main content


Last Updated: April 24, 2019
Result type: Reports
Project Number: SR0615-000
Product Line: Common Drug Review

Generic Name: cyclosporine

Brand Name: Verkazia

Manufacturer: Santen Inc.

Indications: Severe vernal keratoconjunctivitis, pediatric (≥4 years)

Manufacturer Requested Reimbursement Criteria1:

For the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age through adolescence.

Submission Type: New

Project Status: Pending

Call For Patient Input: April 23, 2019

Patient Input Closed: June 12, 2019

Anticipated Date: May 22, 2019

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback